Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of hexyloxy position on antagonistic properties of KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) at muscarinic acetylcholine receptors

A. Janoušková-Randáková, E. Mezeiová, J. Bláhová, N. Chetverikov, E. Dolejší, D. Nelic, L. Prchal, M. Novák, J. Korábečný, J. Jakubík

. 2025 ; 185 (-) : 117977. [pub] 20250314

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009314

Antagonists with a long residence time at the receptors are desired for the possibility of reducing daily doses and side effects. KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) is the long-acting M1-preferring bitopic muscarinic antagonist with a half-life at muscarinic receptors of up to five hours. The binding of 2-hexyloxy and 3-hexyloxy analogues of KH-5 was simulated in silico, compounds were synthesized and their binding and antagonistic properties were measured experimentally in CHO cells expressing individual subtypes of muscarinic acetylcholine receptors. The overall binding affinities of the new compounds were similar to their respective parent compounds. Shifting the hexyloxy chain to ortho and meta positions led to a decrease in potency at the M1 receptor but an increase in potency at the M2 receptor and abolition of long-term antagonism. Preservation of the para position of the hexyloxy chain is essential for the further development of M1-preferring antagonists. Modifications of the basic centre may be the way to improve the geometry of antagonists towards long residence times to obtain the desired long-acting muscarinic antagonists in the future. The additional challenge for further development is the low metabolic stability of compounds.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009314
003      
CZ-PrNML
005      
20250429134850.0
007      
ta
008      
250415e20250314fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2025.117977 $2 doi
035    __
$a (PubMed)40088774
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Janoušková-Randáková, Alena $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
245    10
$a Effect of hexyloxy position on antagonistic properties of KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) at muscarinic acetylcholine receptors / $c A. Janoušková-Randáková, E. Mezeiová, J. Bláhová, N. Chetverikov, E. Dolejší, D. Nelic, L. Prchal, M. Novák, J. Korábečný, J. Jakubík
520    9_
$a Antagonists with a long residence time at the receptors are desired for the possibility of reducing daily doses and side effects. KH-5 (1-{2-[4-(hexyloxy)benzoyloxy]ethyl}-1-methyl-1,2,3,6-tetrahydropyridin-1-ium iodide) is the long-acting M1-preferring bitopic muscarinic antagonist with a half-life at muscarinic receptors of up to five hours. The binding of 2-hexyloxy and 3-hexyloxy analogues of KH-5 was simulated in silico, compounds were synthesized and their binding and antagonistic properties were measured experimentally in CHO cells expressing individual subtypes of muscarinic acetylcholine receptors. The overall binding affinities of the new compounds were similar to their respective parent compounds. Shifting the hexyloxy chain to ortho and meta positions led to a decrease in potency at the M1 receptor but an increase in potency at the M2 receptor and abolition of long-term antagonism. Preservation of the para position of the hexyloxy chain is essential for the further development of M1-preferring antagonists. Modifications of the basic centre may be the way to improve the geometry of antagonists towards long residence times to obtain the desired long-acting muscarinic antagonists in the future. The additional challenge for further development is the low metabolic stability of compounds.
650    _2
$a zvířata $7 D000818
650    _2
$a CHO buňky $7 D016466
650    12
$a Cricetulus $7 D003412
650    12
$a antagonisté muskarinových receptorů $x farmakologie $7 D018727
650    _2
$a receptory muskarinové $x metabolismus $7 D011976
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a receptor muskarinový M1 $x metabolismus $x antagonisté a inhibitory $7 D043643
650    _2
$a pyridiny $x farmakologie $x chemie $7 D011725
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mezeiová, Eva $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Bláhová, Jana $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Chetverikov, Nikolai $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Dolejší, Eva $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Nelic, Dominik $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Prchal, Lukáš $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Novák, Martin $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
700    1_
$a Korábečný, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic. Electronic address: jan.korabecny@fnhk.cz
700    1_
$a Jakubík, Jan $u Department of Neurochemistry, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. Electronic address: jan.jakubik@fgu.cas.cz
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 185 (20250314), s. 117977
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40088774 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134846 $b ABA008
999    __
$a ok $b bmc $g 2310970 $s 1246395
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 185 $c - $d 117977 $e 20250314 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...